
EMV Capital (AIM:EMVC, FRA:NTK1) CEO Dr Ilian Iliev tells Proactive's Stephen Gunnion that the company delivered a strong 2025, with platform revenue reaching just over £3 million, up from zero when the current management team took over in 2025, and assets under management growing 15% to £112 million. Iliev says EMV Capital deliberately "leans in rather than backwards" during difficult markets, using dislocation to find opportunities across deep tech, life sciences, semiconductors, AI and energy efficiency. Portfolio highlights include AMR Bio's progress toward an FDA phase three application, Sofant Technologies' OEM partnerships and Deep Tech Recycling's first pilot plant plans. The ambition is clear: "Reaching and growing beyond the £100 million mark is not a destination. It's a step," with the company now targeting more than £200 million in AUM. Visit Proactive’s YouTube channel for more videos. Don’t forget to like this video, subscribe to the channel and enable notification...
Loading summary